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Smminary Twenty-six previously untreated children, median age 3.4 years, with pelvic rhabdomyosarcoma
(RMS) were seen between 1983 and 1988. Fourteen were girls. The planned strategy was to conserve pelvic
organs, especially the bladder, by using primary chemotherapy, conservative surgery and, in most cases,
radiotherapy. With a median follow-up of 71 months (range 34-103 months) overall survival was 73%, with
no treatment-related death. The bladder salvage rate of 88% in survivors with bladder base,prostate primaries
was much higher than that reported by the United States Intergoup Rhabdomyosarcoma Studies (IRS),
though many of the preserved bladders did not function normally. We identified problems with both
radiological and histological off-treatment monitoring. The overall accuracy of computerised tomographic
(CT') scanning for prediction of tumour recurrence was only 81%, and endoscopic biopsies proved misleading
in four of the ten bladder base/prostate patients monitored by serial cystoscopy. We conclude that a higher
cure rate can be achieved by using intensive chemotherapy/radiotherapy and conservative surgery to treat
children with pelvic RMS. Factors that might contribute to our favourable bladder salvage results, compared
with those of the IRS, include (a) the fact that one of two specialist surgeons monitored and operated on all
these patients and (b) our increasing awareness, during the study, that post-chemotherapy,radiotherapy
histopathology and pelvic CT scan appearances may be misleading. Referral to paediatric centres with special
experience of pelvic RMS may help raise the rate of bladder salvage in these children.
The cure rate for pelvic rhabdomyosarcoma in children is
now approximately 70%, although survival depends on the
tumour stage at diagnosis and the exact site of origin within
the pelvis (Flamant et al., 1990; Raney et al., 1990). Primary
tumours are not always controlled by established treatment
regimens, and some children die from local regrowth of
tumour with or without disseminated disease. Despite this
difficulty with 'local control', most treatment teams now try
to limit the morbidity of surgery. Total cystectomy
cystoprostatectomy, which results in loss of bladder and
sexual function, may be avoided in some children by perfor-
ming surgery after several months of chemotherapy. The
'shrunken' tumour may then be resectable without ablating
pelvic organs and radiotherapy used to treat any residual
disease. Only 11 of 20 children with pelvic rhabdomyosar-
coma treated at this hospital with chemotherapy, radio-
therapy and surgery between 1976 and 1983 survived, and
only six retained their bladders (Broecker et al., 1988). After
1983, we formally adopted a conservative surgical policy to
try to spare children total cystoprostatectomy or total cystec-
tomy.
The main aim of this study was to assess the results of
multimodal therapy, including this conservative surgical
policy, in a paediatric hospital with close liaison between
paediatric oncologists, urologists, histopathologists and
radiologists. Supplementary aims were to determine the value
of serial computerised tomographic (CT) scanning and
endoscopic biopsies in the assessment of local tumour con-
trol
Patients, Investigatioa and Monitoring
We studied all 26 children with pelvic rhabdomyosarcoma,
excluding those with paratesticular tumours, referred to this
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hospital between 1983 and 1988 (Table I). In five cases
surgical resection, not involving ablation of pelvic viscera,
had been attempted elsewhere but none of the children had
received chemotherapy or radiotherapy. Age at presentation
ranged from 3 months to 14.9 years (median 3.4 years) and
14 patients were girls.
The exact sites of the primary tumours were: bladder
base/prostate (13 patients), bladder dome (3), uterus/vagina
(5) and pelvic wall (5). Initial investigations included
posteroantenor and lateral chest radiographs, abdominal
ultrasound, CT scanning of chest and pelvis, radioisotope
bone scan and bilateral iliac bone marrow aspiration. These
studies indicated that 22 patients had group 3 disease
(unresectable local tumour), two group 4 and one each group
I and 2. In the case of 'endophytic' tumours of the bladder,
prostate and vagina accessible by endoscopy, examination
under anaesthetic and biopsies were carried out by one of the
two surgeons (P.G.R. and P.G.D.) involved in the study.
Histological subtypes were embryonal (24) and alveolar
(2).
Reassessments involved sequential contrast-enhanced CT
scans of the pelvis and examinations under anaesthesia with
cystoscopy and endoscopic biopsies at 3 monthly intervals
during treatment and for 2 years from completion of treat-
ment. Thereafter, the same examinations were carried out less
frequently for up to 5 years from completion of treatment.
Patients have been followed till their death or till July 1993.
None has been lost to follow-up.
Treatment Policy
After initial radiological assessment, endoscopy and biopsy
diagnosis, chemotherapy was commenced. Different chemo-
therapy schedules were used, according to the trial current at
the time each child was diagnosed (Table II). The timing and
type of surgery depended on the exact site of the tumour and
the initial response to chemotherapy. Radiotherapy was used
either to treat microscopic post-surgical disease or as the sole
local modality in cases where, in the opinion of the surgeon,
an adequate resection could not be carried out without
ablative surgery. More chemotherapy (9-12 months overall
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Table I
Age at
diagnosis
4.0
6.7
0.75
Site Group
BB/P
Pelvic wall
BB/P
1.3 BB/P
1.0 V/U
6.2 BB,,P
14.9 Uterus
4.3 Pelvic wall
2.0 BB
2.4
2.5
0.3
3.2
4.9
Bladder dome
Pelvic wall
BB/P
V/U
BB/P
2.2 Pelvic wall
3.5
3.4
7.1
1.9
3.9
1.3
0.25
3.1
3.8
2.0
1.5
Bladder dome
Vagina
BBIP
BB/P
BB/P
Pelvic wall
BB/P
Vagina
BB/P
BB/P
Bladder dome
3
3
3
Chemotherapy
Intensive VAC
Intensive VAC
VAC
3 IVA
3 Intensive VAC
3
3
3
3
3
3
3
3
IVA
IVA
IVA
VAC
IVA
IVA
IVA
IVA
IVA
3 VAC, EVD
3
3
4
3
3
4
3
3
3
3
2
IVA
EVD
VAC/EVD
VAC/EVD
VAC/EVD
Palliative care only
VAC
VAC
VAC/EVD
Intensive VAC
Intensive VAC
Radiotherapy (cGy)}
5,000
4,440
4,000 External beam
brachytherapy
4,000
3,000 External beam
brachytherapy
None
None
None
4,000 External beam
brachytherapy
None
3,668
4,000
None
4,000 External beam
brachytherapy
4,500
3,000
Brachytherapy only
5,000
4,000
4,400
None
4,000
4,500
4,000
3,000
None
Outcome
Alive: free of disease
Alive: free of disease
Alive: free of disease
Alive: free of disease
Died of disseminated disease
Alive: free of disease
Alive: free of disease
Alive: free of disease
Alive: free of disease
Alive: free of disease
Died of disseminated disease
Died of disseminated disease
Alive: free of disease
Died of extensive regional
disease
Alive: free of disease
Alive: free of disease
Died of disseminated disease
Alive: free of disease
Alive: free of disease
Died within 4 weeks
of diagnosis
Alive: free of disease
Alive: free of disease
Died of resistant local disease
Alive: free of disease
Alive: free of disease
BB/P, bladder base/prostate primary; V/U, vagina/uterus primary. For definitions of intensive VAC, VAC, IVA and VAC/EVD, see Table
I.
duration) was used to treat residual disease following surgery
and/or radiotherapy.
As far as 'local tumour control' is concered, our app-
roach was as follows. Three operative techniques were used
to remove bladder tumours to try to avoid total cystectomy.
These were (a) partial cystectomy, (b) submucosal resection
for intravesical lesions and (c) resection of tumour masses
adherent to the bladder or prostate without partial cystec-
tomy. Total cystectomy with external diversion was used only
as 'salvage therapy' for intravesical or bladder base/prostate
recurrence after failure of local control by chemotherapy,
radiotherapy and previous conservative surgery. The type
and total dose of radiotherapy (Table l) depended on the
site of the tumour and was by external beam, applicator
(vaginal tumours) or urethral application of iridium wire
within a Foley catheter (base of bladder/prostate lesions).
Results
Not all of the 26 children were treated with primary
chemotherapy, for the following reasons. One received only
palliative care and five, including three with tumours of the
bladder dome, had had primary tumour resections before
referral to our hospital. The three children with bladder
dome primaries survive with intact pelvic viscera after
chemotherapy, although one, group 3 at diagnosis, has also
received radiotherapy. The remaining 20 patients, with
tumours of the bladder base and prostate (12), vagina and
uterus (5) and pelvic wall (3), were treated, according to the
planned treatment strategy, with primary chemotherapy fol-
lowed by conservative surgery, radiotherapy or both (Figure
1). Four of these chikiren did not come to surgery but did
receive radiotherapy; two later relapsed and died of meta-
static disease (one uterus/vagina primary, one pelvic wall)
and two (one bladder/prostate, one uterus/vagina) survive
disease free.
Tabl H Chemotherapy schedules n = 25a
VAC
Vincristine
Actinomycin D
Cyclophosphamide
Intensive VAC
Vincristine
Actinomycin D
Cyclophosphamide
EVD
Vincristine
Etoposide
Doxorubicin
IVA
Vincristine
Actinomycin D
Ifosfamide
1.5 mgm-2asbolus
1.5 mg m-2 as bolus
I g m 2-as bolus
1.5 mgm-2 asboluses, days I and 5
0.5 mg m-2 asboluses, days 1, 3and 5
500 mg m-2 as boluses, days 1, 3 and 5
1.5 mg m-2 asbolus
120 mg m-2 over4 h, days 1-3
25 mg m 2 asbolus, days -2
1.5 mg m-2 as bolus
1.5 mg m-2as bolus
3 g m-2, 3 h infusion with mesna
eachdruggiven ondays 1-3
Chemotherapy consisted of sequential 3 weekly courses of (a)
vincristine, actinomycin D and cyclophosphamide ('VAC` or 'intensive
VAC') (nine patients) or (b) ifosfamide, vincristine and actinomycin D
('IVA') (ten patients) or (c) altemating 'VAC/EVD' (etoposide,
vincristine and doxorubicin) (five patients). One patient received EVD
alone. Courses were given every 3 weeks, or as soon afterwards as
possible. Total duration of chemotherapy was 26-40 weeks. During
radiotherapy, only weekly vincristine was given. "One child (see text)
received only palliative treatment (no chemotherapy).
Sixteen children with tumours of the bladder base/prostate
(11), uterus and vagina (3) and pelvic wall (2) had primary
chemotherapy then local surgical resections. Of the 11 with
bladder base/prostate primaries (Figure 2), two finally under-
went total cystectomy with external diversion after radio-
therapy had apparently failed to eradicate microscopic
residual disease. One of these children died later after
ient Pat
no.
I (1)
2 (2)
3 (3)
4
5
6 (10)
7
8 (8)
9 (5)
10
I1
12
13 (11)
14 (4)
15
16
17
18
19
20
21
22
23 (7)
24
25 (6)
26 (9)10m6 A. ATRA et al.
Table III Summary of radiotherapy, according to tumour site
Radiotherapy Patient category
Bladder prostate Bladder dome Uteruslvagina Pelvic wall Total
Tipe Dose (cGv) (n = 13) (n =3) (n =5) (n =5) (n =26}
External beam alone 3,000-5,000 9 1 1 3 14
Brachytherapy alone 1.000 - - I - 1
External beam 3,000-4,000 3 - I - 4
and brachytherapy 1.000-2,000 -
None - 1 2 2 2a 7
"One palliative treatment only.
Pelvic rhabdomyosarcoma
26 patients
Palliative care only
1 died(j
Bladder dome
3 alive( ei)(
+ 3 functional bladders
Bladder t)
1 alive
cystectoi
Primary resection
5
wse Pelvic wall
1 died(iI
my
No surgery
4.
Primary chemotherapy
20
Delayed surgery
165
Bladder base
1 alive with(9)
functional bladder
Uterus/vagina
2
1 alive with
functional bladder(17)
1 died of systemic disease ®
Bladder base
11
8 alive(
+ 7 functional bladders
3 died @X)@)
Uterus/vagina
3
3 alive
+ 3 functional bladders
Pelvic wall
2
2 alive
+ 2 functional bladders
Fugwe 1 Flow chart showing outcome in all 26 patients. The unique patient numbers are provided in circles, e.g. 16, and those
with functional bladders are indicated.
developing lung and bony metastases; no tumour was
identified in the resected specimen from the second patient,
despite apparent preoperative microscopic urethral disease,
and he remains disease free. Three chikln underwent partial
cystectomy and radiotherapy. One has since died of dissemi-
nated disease. Of the two survivors, one has required an
ileocystoplasty and Mitrofanoff stoma (Mitrofanoff, 1980),
complicated by a vesicovaginal fistula, which was subse-
quently closed surgically, and the other has incomplete
urinary control. Three patients underwent submucosal resec-
tions and radiotherapy. One of these children has died after
local recurre of tumour, despite subsequent prostatec-
tomy/partial cystectomy and external beam radiotherapy.
Both the survivors have incomplete urinary control. Three
patients have had extravesical resections, one involving a
hysterectomy. They have complete urinary control, but one
has a colourethral fistula. Clearly, some patients within this
group will require continence surgery in the future, and the
last-mentioned child will require surgical treatment for the
fistula. In addition, all three patients with uterine and vaginal
primaries have undergone hysterectomy and radiotherapy,
one with vaginectomy. She will also require reconstructive
surgery. Two patients with tumours of the pelvic wall have
undergone resection of residual masses after initial
chemotherapy, one without post-operative radiotherapy, and
are well without obvious functional sequelae.
There were no treatment-related deaths but, overall, 7
(27%) of the 26 children have died from their cancer (Figure
1). One child who presented with an advanced, disseminated
tumour received palliative treatment only and died within 4
weeks of diagnosis. Of the remaining 25 children, four
relapsed with disseminated tumour and died at a median of
12 months (range 3-41 months) from completion of initial
treatment and 3 months (range 2-32 months) after treatment
for relapse. One died of extensive regional disease 2 months
after initial treatment and one of local disease 16 months
after initial treatment. All 19 survivors are disease free from
34 to 103 months (median 71 months) from completion of
treatment, and 17 retain their bladders. The other two
patients (patients 4 and 9) relapsed locally 4 and 8 months
from completion of initial treatment but survive 29 and 72
months after cystoprostatectomy and firther chemo-
therapy.
Of the 12 children with bladder base/prostate primaries
treated with primary chemotherapy, nine are alive and
disease free; eight of these patients retain their bladder. The
last adverse 'event' was 40 months from diagnosis, so most of
the survivors are likely to be cured of their malignancy.
Details of bladder function in children cured of bladder/
prostate primaries are provided in a separate publication
(Yeung et al., 1994). The numbers of the children in Yeung's
study are indicated in parenthesis in Table I. Of the four
survivors from vaginal or uterus primary tumours, one had
hysterovaginectomy, two had hysterectomies and one
Pelvic wall
1 died(SD
I
. _
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Bladder base/prostate rhabdomyosarcoma
11
* 2 Total cystectomy
1 alive(®)
1 died of disseminated disease(
- 3 Submucosal resection
2 alive &!)
1 died of disseminated disease (
* 3 Partial cystectomy
2 alive ®(JI)
1 died of disseminated disease ()
-* 3 Extravesical resection
Flgwe 2 Flow chart for 11 patients with bladder base or pros-
tate primares and primaiy chemotherapy. Seven of eight sur-
vivors retained their bladder.
developed vaginal stenosis. There are therefore considerable
late sequelae of this 'conservative' treatment approach.
Of the 26 children, 22 were referred for CT scans of the
pelvis. Ninety-nine scans were performed, but surgical cor-
relation, i.e. exploratory surgery carried out within 6 weeks
of CT scaning, was available only in 54 instances (55%).
The results of CT agreed with surgical figs in only 44
(81%) of these comparisons. In 5/10 instances of disagree-
ment, CT sug that tumour was present but this was not
confirmed by surgery or biopsy and none of these patients
has relapsed. In the five other cases there was no evidence of
tumour on CT but tumour, thought to be present at surgery,
was confirmed on histological xaminaton.
Among the ten patients with bladder base/prostate lesions
who achieved complete radiological remission, serial biopsies
proved misleading in four. Apparently viable 'rhabdomyo-
blasts' were present in biopsies from three patients who have
not relapsed, despite having no further treatment from 11 to
65 months (median 48 months) since the biopsy. The fourth
child (already mentioned) underwent total cystoprostatec-
tomy but no tumour was found in the resected specumen.
Poor control of systemic disease by chemotherapy was the
main reason for treatment failure. A variety of chemotherapy
regimens were used depending upon the protocol in use at
the time of diagnosis. Because of the small number of child-
ren in each subgroup, no comment on their relative efficacy
can be made, and this discussion focuses on the impact of
'local' therapy (conservative surgery and radiotherapy) on
treatment outcome. Our findings indicate that preservation of
the bladder has not prejudiced the overall cure rate, though it
is possible that the one patient who died of local disease
might have benefited from earlier anterior exenteration.
There were eight treatment failures. Two patients, one with
a bladder base/prostate tumour and one with a pelvic wall
primary and extensive regional spread, did not achieve com-
plete remission; both died with uncontroled local disease. Six
patients relapsed after apparent complete response. The four
children with metastases all died, but two boys with only a
local recurrence were 'salvaged' with further chemotherapy
or radiotherapy and cystoprostatectomy.
Because of the small numbers of patients in this series,
differences in outcome for the different primary sites of
tumour cannot be compared for statistical signifi , but
three of five patients with pelvic wall tumours presented with
either metastases or extensive local/regional disease and died,
and a fourth child soon relapsed with metastases. Larger
numbers would be needed to examine the possibility that
children with primary tumours at this site present 'late' and
have a relatively poor prognosis; those chiklden with bladder
and genital tract tumours tend to present with urinary symp-
toms and bleeding, possibly at an earlier stage (Maureret al.,
1993). Primary tumours of the bladder dome are especially
amenable to surgical excision (Hays et al., 1990), and all
three children in our study survive with good bladder func-
tion.
There is considerable morbidity among the other survivors
with preserved bladders, probably the consequence of loss of
functional bladder volume and sphincter damage (Yeung et
al., 1994). Surgery, radiotherapy, and chemotherapy all con-
tribute. The type of morbidity depends on both the primary
tumour site and the treatment approach. Some of our
patients have incomplete urinary control. Those children with
bladder base/prostate lesions are most likely to suffer from
this complication owing to direct interference with sphincter
mechanisms. Those with female genital tract primaries suffer
reduction or loss of reproductive capacity. One has had a
vaginectomy and one patient who had radiotherapy without
surgery has vaginal stenosis. In males the local bladder base/
prostate tumour and its treatment may cause impotence and
sterility by interfering with autonomic nerves, the vasa
deferentia and ejaculatory mechanisms, but clearly this form
of morbidity is much less of an immediate handicap than
total cystoprostatectomy.
Continence and reconstructive vaginal surgery is likely to
be complicated by prior radiotherapy (Mclorie et al., 1989).
For example, the child in this series who had an ieocysto-
plasty later developed a vesicovaginal fistula in the tissue
irradiated by external beam and iridium implant, though this
has since been surgicaly closed, and the boy with a col-
ovescl fistula had received radiotherapy by external beam.
However, radiotherapy is an essential component of a con-
servative surgical policy.
Accurate assessment of local disease and its response to
treatment is essential in order to plan the timing and extent
of surgery. Our results demonstrate that both CT scanning
and serial endoscopic assessment and biopsy are imperfect
monitoring tools. Chemotherapy, radiotherapy and previous
surgery may also impair interpretation. It can be difficult, for
instance, to distinguish residual tumour from normal bladder
muscle, both at endoscopy and on CT. Small residual tumour
masses at the bladder base are not easily imaged with axial
sections on CT. It is therefore not surprising to find that CT
is incorrect in the assessment of residual disease in around
20% of cases. Multiplanar imaging with magnetic resonance
(MRI) has been shown to be of value in the assessment of
adult bladder cancer (Husband et al., 1989). Ultrasound may
be useful in the assessment of small residual masses and, as
has been demonstrated in adults, transrectal probes provide
good images of the prostate region (Brooman et al., 1981).
However, neither MRI nor ultrasound was ased in this
study.
Our study highlights a problem in the managemt of
patients who, after completion of chemotherapy and/or
radiotherapy, have rhabdomyoblast-like cells in endoscopic
biopsies, without macroscopic evidence of recurrence. In four
patients rhabdomyoblasts were present in biopsies from
previously involved areas ofthe bladder and/or bladder neck,
though no macroscopic tumour was visible at the time of
biopsy. As no residual tumour was present in the resected
total cystoprostatectomy specimen of the first of these
patients, no additional treatment was given to the other three
childrn and, after a median follow-up of 48 months from
biopsy, none of these patient has had tumour recurrence.1iN A. ATRA et a].
This indicates that the presence of apparently viable rhab-
domyoblasts in a small biopsy specimen is not necessarily an
indicator of biologically malignant behaviour.
Our 'bladder salvage' rate is now much better than it was
in the 1970s and early 1980s (Flamant et al., 1990) and
(albeit with small numbers) superior to that of the IRS I and
II studies (Maurer et al., 1988; Mclone et al., 1989; Hays et
al., 1990; Maurer et al., 1993). We accept that the preserved
bladder may have impaired fumction and that reconstruction
may be required, but our results encourage us to try to refine
our current surgical conservative treatment approach rather
than revert to a policy of early cystectomy/cystoprostatec-
tomy. The close collaboration that develops between a team
in a single institution, such as ours, when dealing with these
patients is probably crucial. We suggest that organ preserva-
tion, with 'acceptable' function, with or without reconstruc-
tive surgery, may be an achievable goal if patients are
referred to specialised centres where experience in and re-
sources for the management of this uncommon condition are
concentrated.
Six of the seven children in this series who died had
uncontrollable metastatic disease, so it is evident that better
chemotherapy is needed (Womer, 1993). Possibilities cur-
rently under investigation, are (a) that ifosphamide might be
superior to cyclophosphamide (the 'IVA' regime rather than
'VAC') , (b) that multidrug resistance (Chan et al., 1990)
might be reversed by cyclosporin or verapamil and that (c)
use of 'continuous' chemotherapy, especially etoposide, might
be more effective than 'pulsed' administration. Improvement
in the control of systemic disease would almost certainly also
boost the 'local control' rate and allow more children to
complete treatment with intact, and possibly non-irradiated,
pelvic organs.
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